ACT-GLOBAL Adaptive Platform Trial for Stroke

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

NCT Number	NCT06352632
Lead Sponsor	The George Institute Collaborators: University of Calgary, Berry Consultants
Conditions	Stroke
Enrollment	20,000 participants
Start Date	2024-09-26
Primary Completion	2034-09 (estimated)
Study Completion	2034-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-08